Clinical trials: Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.
- Trial name
- CLIPS (NCT06512883)
- Testing
- Benralizumab
- Where
- 15 sites in United States, Brazil and 8 more
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as…
- Conditions
- Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
- Trial name
- ROSY-F (NCT07444567)
- Testing
- Benralizumab
- Where
- 47 sites in United States, Argentina and 12 more
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA)
Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)
This observational study aims to evaluate the long-term effectiveness and safety of mepolizumab 300 mg/4 weeks in adults with eosinophilic granulomatosis with polyangiitis (EGPA) in the European real-life setting.
- Trial name
- Mepo LTF (NCT07591753)
- Testing
- Mepolizumab 300 mg
- Where
- Italy
- Volunteers
- 299 people
- Sponsor
- European EGPA Study Group
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Benralizumab Effectiveness in EGPA
This is a multicenter, retro-prospective observational study evaluating the effectiveness and safety of benralizumab in adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) in a real-world setting.
- Trial name
- BELONG-EGPA (NCT07815886)
- Testing
- Benralizumab 30 mg/ml
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- European EGPA Study Group
Sinus Disease, EGPA - Eosinophilic Granulomatosis With Polyangiitis
Effectiveness on Sino-Nasal Symptoms Of Mepolizumab 300
OBJECTIVES The primary objective of this study is evaluating the reduction of dimension of nasal polyps measured with Nasal Polyp Endoscopic Score (NPS) The secondary objective is to evaluate the improvement in nasal symptoms and…
- Conditions
- Sinus Disease, EGPA - Eosinophilic Granulomatosis With Polyangiitis, Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
- Trial name
- MEPO300REAL (NCT07592104)
- Testing
- Mepolizumab 300 mg
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
EGPA - Eosinophilic Granulomatosis With Polyangiitis
Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis
RACEMATE is a phase 2b, multicentre, randomised, double-blinded, placebo-controlled study designed to explore the efficacy and mechanism of action of tezepelumab in adults with eosinophilic granulomatosis with polyangiitis (EGPA).
- Trial name
- RACEMATE (NCT06230354)
- Testing
- Tezepelumab
- Where
- 12 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Imperial College London
Asthma, EGPA(Eosinophilic Granulomatosis With Polyangiitis)
FASENRA Regulatory Postmarketing Surveillance in Korea
As part of a post approval commitment, the MFDS has requested a study to characterize safety in patients who are treated with FASENRA for severe eosinophilic asthma and/or eosinophilic granulomatosis with polyangiitis (EGPA) by…
- Trial name
- FASENRA rPMS (NCT05091333)
- Where
- 5 sites in South Korea
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Vasculitis, Behcet's Disease
Vasculitis Pregnancy Registry
The purpose of this study is to learn about the experience of women with vasculitis who become pregnant. In particular, the study will consist of several online surveys to assess 1.
- Conditions
- Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis
- Trial name
- V-PREG (NCT02593565)
- Testing
- Online questionnaires
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Pennsylvania
Cryoglobulinemic Vasculitis (CV), Drug-induced Vasculitis
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Multi-center observational study to evaluate the histopathology and transcriptome of cutaneous lesions in patients with several different types of vasculitis.
- Conditions
- Cryoglobulinemic Vasculitis (CV), Drug-induced Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), IgA Vasculitis
- Trial name
- CUTIS (NCT03004326)
- Where
- 10 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Peter Merkel
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS)
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
Naltrexone is an FDA approved drug (for alcoholism) that has found widespread use "off-label" to treat pain and improve quality of life at much lower doses than are used for the approved indication.
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis
- Trial name
- LoDoNaVasc (NCT03482479)
- Testing
- Naltrexone Hydrochloride
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- University of Pennsylvania
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Rituximab in Eosinophilic Granulomatosis With Polyangiitis
Phase III, comparative, multicenter, randomized, controlled, double-blind and superiority research, comparing rituximab-based regimen with conventional therapeutic strategy for the induction of remission in patients with…
- Trial name
- REOVAS (NCT02807103)
- Testing
- Rituximab, Cyclophosphamide
- Where
- France
- Volunteers
- 107 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma
Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA
Aim of the study is to identify potential biomarkers, through a proteomic approach, which could be used to evaluate organ damage and predict the response to mepolizumab in a cohort of patients affected by EGPA.
- Conditions
- EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma, Eosinophilic Asthma
- Trial name
- BEOMICS (NCT07343661)
- Testing
- Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Azienda Ospedaliero Universitaria di Cagliari
EGPA - Eosinophilic Granulomatosis With Polyangiitis, HES - Hypereosinophilic Syndrome
The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome
The purpose of this study is to collect clinical, laboratory, and instrumental data from patients with eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome, which will then be analyzed using artificial…
- Trial name
- NCT07275190
- Testing
- Blood draw for the laboratory assessment
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Eosinophilic Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Eosinophil Subpopulations in Eosinophilic-associated Diseases
This single-center, non-commercial study will involve 160 participants (80 with eosinophilic asthma (EA), 30 with eosinophilic granulomatosis with polyangiitis (EGPA), 25 with hypereosinophilic syndrome (HES), and 25 healthy…
- Conditions
- Eosinophilic Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
- Trial name
- IREOS (NCT06911775)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University of Florence
EGPA - Eosinophilic Granulomatosis With Polyangiitis
eGPA and Local Inflammation Within the Ear, Nose and Throat Area
Rationale: Eosinophilic Granulomatosis with Polyangiitis (eGPA), eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are airway diseases where eosinophils and interleukine-5 are involved in the pathogenesis.
- Trial name
- NCT06298448
- Testing
- laboratory experiments before and after mepolizumab treatment
- Where
- Netherlands
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Eosinophilic Asthma, EGPA - Eosinophilic Granulomatosis With Polyangiitis
Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils
Introduction: The etiology and therapy of eosinophilic lung diseases are still poorly understood. For individual forms of disease, such as eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA), new…
- Conditions
- Eosinophilic Asthma, EGPA - Eosinophilic Granulomatosis With Polyangiitis, Samter Triad, HES - Hypereosinophilic Syndrome
- Trial name
- PROMETHEos (NCT04538937)
- Testing
- no intervention
- Where
- Austria
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS)
The ANCA Vasculitis Questionnaire (AAV-PRO©)
The aim of this project is to develop a disease specific patient reported outcome measure (PROM) for patients with AAV (the AAV-PRO).
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (Wegener's) (GPA), Wegener Granulomatosis (WG)
- Trial name
- AAV-PRO (NCT02507024)
- Testing
- Online questionnaire
- Where
- 2 sites in United States
- Volunteers
- 280 people
- Sponsor
- University of Pennsylvania